Metronomic Capecitabine in Stage III Gastric Cancer

Recruiting now · Phase 3

Conditions studied: Gastric Cancer

In brief

The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.

Key facts

Study ID

NCT06313567

Run by

Fudan University

People needed

722

Starts

2024-03-10

Expected to finish

2029-03-10

Last updated by the study team

2024-07-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lower age limit of research subjects 18 years old and upper age limit of 80 years old.
• Be proven to be primary adenocarcinoma of gastric cancer and staged III by pathological evidences
• R0 gastrectomy with D2 lymphadenectomy
• ECOG (ECOG score standard) performance status of 0 or 1 and expected to survive more than 6 months
• No contraindications, including normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥3.5 x 109 /L, NEU≥1.2 x 109 /L,PLT≥90 x 109 /L and HGB≥80g/L).

You may not qualify if…

• History of chemotherapy, radiotherapy, immunotherapy or target therapy
• Multiple primary tumors
• Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases
• Unavailable for R0 resection and D2 lymph node dissection.
• Patients with stage IV gastric cancer

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.